野生型KRAS是帕尼单抗在转移性结直肠癌患者中发挥疗效的必要条件
这项III期转移性结直肠癌试验比较帕尼单抗单药与最佳支持治疗,在427例可评估KRAS状态的患者中分析疗效与KRAS状态的关系。野生型KRAS组帕尼单抗对无进展生存期的效果显著优于突变组(HR 0.45 vs 0.99,P<.0001)。结论认为帕尼单抗单药疗效仅限于野生型KRAS肿瘤患者,选择帕尼单抗单药治疗时应考虑KRAS状态。
要点
- 野生型KRAS组帕尼单抗较最佳支持治疗显著改善无进展生存期(HR 0.45)。
- 突变型KRAS组帕尼单抗对无进展生存期无显著获益(HR 0.99)。
- 野生型KRAS组帕尼单抗缓解率为17%,突变组为0%。
核心结论
- 帕尼单抗单药在转移性结直肠癌中的疗效仅限于野生型KRAS肿瘤患者。
- 选择转移性结直肠癌患者作为帕尼单抗单药治疗候选者时应考虑KRAS状态。
研究设计与样本
- III期转移性结直肠癌试验,比较帕尼单抗单药与最佳支持治疗(BSC)。
- 采用聚合酶链反应检测肿瘤组织DNA中的KRAS突变。
- 463例患者中427例(92%)确定KRAS状态(帕尼单抗208例,最佳支持治疗219例)。
主要发现
- 43%的患者发现KRAS突变。
- 野生型KRAS组帕尼单抗对无进展生存期的治疗效果(HR 0.45;95%CI 0.34至0.59)显著大于突变组(HR 0.99;95%CI 0.73至1.36),P<.0001。
- 野生型KRAS组中位无进展生存期帕尼单抗为12.3周,最佳支持治疗为7.3周。
- 帕尼单抗缓解率野生型KRAS组为17%,突变组为0%。
- 野生型KRAS患者总生存期更长(HR 0.67;95%CI 0.55至0.82;治疗组合并分析)。
临床怎么用
- 原文结论认为选择转移性结直肠癌患者作为帕尼单抗单药治疗候选者时应考虑KRAS状态。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Panitumumab, a fully human antibody against the epidermal growth factor receptor (EGFR), has activity in a subset of patients with metastatic colorectal cancer (mCRC). Although activating mutations in KRAS, a small G-protein downstream of EGFR, correlate with poor response to anti-EGFR antibodies in mCRC, their role as a selection marker has not been established in randomized trials. PATIENTS AND METHODS: KRAS mutations were detected using polymerase chain reaction on DNA from tumor sections collected in a phase III mCRC trial comparing panitumumab monotherapy to best supportive care (BSC). We tested whether the effect of panitumumab on progression-free survival (PFS) differed by KRAS status. RESULTS: KRAS status was ascertained in 427 (92%) of 463 patients (208 panitumumab, 219 BSC). KRAS mutations were found in 43% of patients. The treatment effect on PFS in the wild-type (WT) KRAS group (hazard ratio [HR], 0.45; 95% CI: 0.34 to 0.59) was significantly greater (P < .0001) than in the mutant group (HR, 0.99; 95% CI, 0.73 to 1.36). Median PFS in the WT KRAS group was 12.3 weeks for panitumumab and 7.3 weeks for BSC. Response rates to panitumumab were 17% and 0%, for the WT and mutant groups, respectively. WT KRAS patients had longer overall survival (HR, 0.67; 95% CI, 0.55 to 0.82; treatment arms combined). Consistent with longer exposure, more grade III treatment-related toxicities occurred in the WT KRAS group. No significant differences in toxicity were observed between the WT KRAS group and the overall population. CONCLUSION: Panitumumab monotherapy efficacy in mCRC is confined to patients with WT KRAS tumors. KRAS status should be considered in selecting patients with mCRC as candidates for panitumumab monotherapy.
引用
- Amado RG, Wolf M, Peeters M, et al. Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer. J Clin Oncol. 2023. PMID: 37315390. doi:10.1200/JCO.22.02758
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。